Cancer treatment and research communications最新文献

{"title":"Retrospective evaluation of the \"neutrophil-lymphocyte ratio\" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial","authors":"Chiara Mattioli ,&nbsp;Emanuela Olmetto ,&nbsp;Marco Banini ,&nbsp;Pietro Garlatti ,&nbsp;Saverio Caini ,&nbsp;Marco Del Riccio ,&nbsp;Giovanna Finocchiaro ,&nbsp;Paolo Borghetti ,&nbsp;Sara Pilotto ,&nbsp;Giulio Metro ,&nbsp;Francesco Grossi ,&nbsp;Gabriella Farina ,&nbsp;Fausto Meriggi ,&nbsp;Antonio Chella ,&nbsp;Elisa Roca ,&nbsp;Cristina Zannori ,&nbsp;Angelo Delmonte ,&nbsp;Alessandro Russo ,&nbsp;Marianna Macerelli ,&nbsp;Carlo Genova ,&nbsp;Vieri Scotti","doi":"10.1016/j.ctarc.2026.101132","DOIUrl":"10.1016/j.ctarc.2026.101132","url":null,"abstract":"<div><h3>Background</h3><div>Very little is known regarding the clinical value of inflammatory blood markers, such as NLR, Systemic Immune Inflammation (SII), derived NLR (dNLR) and Lung Immune Prognostic Index (LIPI) in stage III NSCLC patients treated as per PACIFIC regimen.</div></div><div><h3>Methods</h3><div>Neutrality trial (ESR-19–20410) is a retrospective multicentric study aimed at assessing the clinical impact of these blood inflammatory indexes on the clinical outcomes of such population. Unresectable stage III NSCLC patients were enrolled in two cohorts: the Durvalumab one, encompassing 94 patients treated within the Italian EAP, and the historical one, including 96 patients treated with radio-chemotherapy alone. Blood count tests were recorded at established time points from start of treatment.</div></div><div><h3>Results</h3><div>In the Durvalumab cohort, baseline NLR ≥5 significantly correlated with PFS (HR 1.93, 95% CI 1.12–3.30, <em>p</em> &lt; 0.017; median 38.2 vs 21.4 months for NLR&lt;5 and ≥5, p 0.015). The dNLR at baseline was also significantly correlated with PFS, with an HR of 2.14 (95% CI 1.14–4.02, <em>p</em> = 0.018; median 35.6 vs 18.7 months for dNLR&lt;3 vs ≥3, <em>p</em> = 0.016). The median PFS of the good prognostic LIPI index group was significantly better than the intermediate group (p-value &lt; 0.004), and the poor group (p-value &lt; 0.039). In the historical cohort, SII correlated significantly with PFS when considered as a continuous variable (HR for each increment by 1: 1.02, 95% CI 1.01–1.03; p 0.007).</div></div><div><h3>Conclusion</h3><div>Neutrality trial confirmed the potential prognostic role of blood inflammatory indexes in patients with unresectable stage III NSCLC treated as per PACIFIC regimen.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101132"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microcalcifications matter: Diagnostic and biological differences in DCIS","authors":"Luca Nicosia ,&nbsp;Luciano Mariano ,&nbsp;Carmen Mallardi ,&nbsp;Filippo Pesapane ,&nbsp;Lorenza Meneghetti ,&nbsp;Francesca Abbate ,&nbsp;Samuele Frassoni ,&nbsp;Vincenzo Bagnardi ,&nbsp;Cristian Gialain ,&nbsp;Giovanni Corso ,&nbsp;Nicola Fusco ,&nbsp;Enrico Cassano","doi":"10.1016/j.ctarc.2026.101135","DOIUrl":"10.1016/j.ctarc.2026.101135","url":null,"abstract":"<div><h3>Introduction</h3><div>Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer increasingly detected through screening. While microcalcifications are the most common feature, a subset lacks them, posing diagnostic and management challenges. We investigated the relationship between radiological presentation (calcified vs. non-calcified) and the risk of upstaging to invasive carcinoma.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively analyzed 196 patients with biopsy-proven DCIS who underwent surgery between 2000 and 2023. Ninety-eight (98) non-calcified cases diagnosed via ultrasound-guided vacuum-assisted biopsy were matched with 98 calcified cases diagnosed via stereotactic vacuum-assisted biopsy, based on age, grade, and macroscopic removal. We investigated the associations between upstaging and potential predictors, including calcification status, age at biopsy, lesion size, and histologic grade at biopsy.</div></div><div><h3>Results</h3><div>The overall underestimation rate was 13.8% (27/196). Non-calcified DCIS showed a higher upstaging rate than calcified DCIS (19% vs. 8%; multivariable OR for calcified DCIS: 0.31, 95% CI: 0.12–0.78, p = 0.013). Larger lesions increased the risk of underestimation (OR per 5 mm: 1.21, 95% CI: 1.06–1.38, p = 0.005), while age was not significant (OR per 5 years: 1.01, p = 0.91).</div></div><div><h3>Conclusions</h3><div>Non-calcified DCIS and larger lesion size seemed independently associated with upstaging to invasive carcinoma, highlighting the clinical relevance of radiological presentation for risk stratification.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101135"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: a retrospective multi-institutional survey in the Kinki district of Japan","authors":"Yasushi Mabuchi ,&nbsp;Kyoka Takahashi ,&nbsp;Takuya Yokoe ,&nbsp;Masato Kita ,&nbsp;Shinichi Terada ,&nbsp;Tomohito Tanaka ,&nbsp;Masahide Ohmichi ,&nbsp;Haruka Suzuki ,&nbsp;Junzo Hamanishi ,&nbsp;Masaki Mandai ,&nbsp;Takuya Noda ,&nbsp;Takeshi Fukuda ,&nbsp;Toshiyuki Sumi ,&nbsp;Yoko Kashima ,&nbsp;Hidekatsu Nakai ,&nbsp;Noriomi Matsumura ,&nbsp;Yutaka Yoneoka ,&nbsp;Tsukuru Amano ,&nbsp;Mariko Matsumoto ,&nbsp;Tomoharu Okubo ,&nbsp;Kazuhiko Ino","doi":"10.1016/j.ctarc.2026.101157","DOIUrl":"10.1016/j.ctarc.2026.101157","url":null,"abstract":"<div><h3>Background</h3><div>Lenvatinib plus pembrolizumab therapy has recently attracted attention as a new treatment option. However limited information is currently available based on large-scale clinical experience in Japanese patients. The present study examined patients with advanced or recurrent endometrial cancer who were treated with lenvatinib and pembrolizumab in the Kinki district of Japan.</div></div><div><h3>Methods</h3><div>A total of 161 patients with advanced or recurrent endometrial cancer who received lenvatinib and pembrolizumab were enrolled from 13 hospitals in the Kinki district between December 2021 and July 2024. We retrospectively reviewed their medical records.</div></div><div><h3>Results</h3><div>In the overall patient population, median overall survival (OS) was 27 months and median progression-free survival (PFS) was 9 months. In patients with proficient mismatch repair (pMMR), median OS was 21 months and median PFS was 8 months. The cohort included 14 patients with carcinosarcoma, for whom median OS was 20 months and median PFS was 9 months. A univariate analysis showed that the histological subtype and MMR status correlated with PFS, while the histological subtype, MMR status, and platinum-free interval correlated with OS. A multivariate analysis identified age and the histological subtype as significant factors for PFS, while the histological subtype, MMR status, and platinum-free interval correlated with OS.</div></div><div><h3>Conclusion</h3><div>The combination of lenvatinib and pembrolizumab showed favorable treatment outcomes for patients with advanced or recurrent endometrial cancer in the Kinki district. This regimen appeared to be more effective for patients with a longer platinum-free interval (&gt;6 months), or endometrioid carcinoma, or deficient MMR.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101157"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of IHC, AMRS-PCR, and ddPCR for BRAF V600E mutation detection in papillary thyroid carcinoma","authors":"Chen Chang ,&nbsp;Guodong Fang ,&nbsp;Jianyuan Lei ,&nbsp;Lele Liu ,&nbsp;Guorong Wang ,&nbsp;Wensheng Li","doi":"10.1016/j.ctarc.2025.101085","DOIUrl":"10.1016/j.ctarc.2025.101085","url":null,"abstract":"<div><h3>Background</h3><div>The BRAF V600E mutation is the most frequent driver alteration in papillary thyroid carcinoma (PTC) and plays an important role in diagnosis, risk stratification, and treatment planning. Commonly used detection methods include immunohistochemistry (IHC), amplification-refractory mutation system PCR (AMRS-PCR), and droplet digital PCR (ddPCR). However, their relative performance and their ability to identify low-frequency mutations have not been fully clarified.</div></div><div><h3>Methods</h3><div>This retrospective study included 1571 patients diagnosed with PTC between December 2021 and January 2025. All patients underwent IHC testing, and 871 also received AMRS-PCR for BRAF V600E detection. Sixty cases with discordant IHC and AMRS-PCR results were further analyzed using ddPCR. Detection rates, concordance, sensitivity, specificity, and variant allele frequency (VAF) were compared across the three methods.</div></div><div><h3>Results</h3><div>Among the 871 patients with both IHC and AMRS-PCR results, the overall concordance rate was 93.2 %, and 59 cases showed discordant findings. ddPCR confirmed the presence of BRAF V600E in 24 discordant cases (40.7 %). The ddPCR positivity rate was higher in the IHC-negative and AMRS-PCR-positive group than in the IHC-positive and AMRS-PCR-negative group (52.2 % vs. 33.3 %, <em>P</em> = 0.033), and the former group also showed a markedly higher VAF (mean 6.97 % vs. 2.82 %). AMRS-PCR demonstrated better sensitivity and specificity (75.0 % and 85.7 %) than IHC (25.0 % and 14.3 %).</div></div><div><h3>Conclusion</h3><div>AMRS-PCR provides greater sensitivity and specificity than IHC for detecting BRAF V600E mutations and is appropriate for routine molecular testing. ddPCR offers excellent sensitivity for low-frequency mutations and is valuable for resolving discordant results. A multimodal testing strategy may improve detection accuracy and support personalized management of patients with PTC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101085"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary study of androgen receptor expression in oral lichen planus and oral squamous cell carcinoma: A comparative cross-sectional analysis","authors":"Shiva Shirazian ,&nbsp;Saeide Tehranchi ,&nbsp;Nazanin Mahdavi ,&nbsp;Mohammad Javad Kharazifard ,&nbsp;Mahdieh-Sadat Moosavi","doi":"10.1016/j.ctarc.2025.101050","DOIUrl":"10.1016/j.ctarc.2025.101050","url":null,"abstract":"<div><h3>Purpose</h3><div><strong>:</strong> Androgen receptor (AR) signaling is known to contribute to the progression of various cancers, including oral squamous cell carcinoma (OSCC). However, its role in oral lichen planus (OLP), a chronic inflammatory disorder with malignant potential, remains poorly understood. This preliminary study aimed to evaluate AR expression in OLP and OSCC tissues and explore its potential involvement in their pathogenesis.</div></div><div><h3>Methods</h3><div><strong>:</strong> A cross-sectional study was conducted using 50 paraffin-embedded tissue samples (25 OLP and 25 OSCC). AR expression was assessed by immunohistochemistry and graded based on the percentage of positively stained cells. Statistical analysis was performed to compare AR expression between groups.</div></div><div><h3>Results</h3><div><strong>:</strong> AR expression was observed in 28% of OLP and 40% of OSCC samples. No significant difference in AR expression was found between OLP and OSCC tissues. In OSCC, AR expression did not significantly vary across tumor grades. Notably, age-matched analysis showed similar AR expression patterns in both groups.</div></div><div><h3>Conclusion</h3><div><strong>:</strong> These preliminary findings suggest that AR signaling may contribute to shared molecular pathways linking chronic inflammation with carcinogenesis. Further large-scale studies are required to confirm these observations.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101050"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An observational study to identify selection criteria for initiation of different first line treatment options in patients with non-small cell lung cancer","authors":"Marina Labor ,&nbsp;Andreas Koulouris ,&nbsp;Marcus Skribek ,&nbsp;Simon Ekman ,&nbsp;Jon Goenechea ,&nbsp;Adam Sierakowiak ,&nbsp;Hanne Wessel Lund ,&nbsp;Martina Recalde ,&nbsp;Georgios Tsakonas ,&nbsp;Hirsh Koyi","doi":"10.1016/j.ctarc.2026.101213","DOIUrl":"10.1016/j.ctarc.2026.101213","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer remains a leading cause of cancer-related mortality. Despite advancements in diagnostics and treatment, clinical decision-making often incorporates factors not captured in clinical trials or registries. This study aimed to identify key parameters influencing treatment choices for untreated stage IV non-small cell lung cancer (NSCLC) patients using real-world data from Sweden.</div></div><div><h3>Methods</h3><div>A multicenter study between April 2021 and April 2023 involving 359 patients from five Swedish hospitals was conducted to explore factors influencing treatment decisions for untreated stage IV NSCLC. A standardized data collection tool, developed for this study was used to gather key clinical and demographic variables—such as performance status, age, comorbidities, histology, molecular profiling, and selected treatment, as well as how the treatment decision was made—based on information extracted from electronic medical records.</div></div><div><h3>Results</h3><div>Chemotherapy combined with immunotherapy was the most common treatment (39%), followed by best supportive care (20%) and chemotherapy alone (14%). Performance status and age were the most frequently cited factors influencing treatment decisions. Multidisciplinary team decisions guided most of the cases, and approximately two-thirds of treatments (66%) were influenced by national guidelines, based on physician reports.</div></div><div><h3>Conclusion</h3><div>The study underscores the dynamic nature of NSCLC and the importance of a multifaceted approach to treatment decisions involving patient-specific factors, multidisciplinary team input, and adherence to guidelines.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101213"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of using intraoperative nomograms with one-step nucleic acid amplification to omit axillary lymph node dissection in patients with breast cancer who underwent mastectomy","authors":"Takanori Kin,&nbsp;Nanae Masunaga,&nbsp;Chieko Mishima,&nbsp;Masami Tsukabe,&nbsp;Yoshiaki Sota,&nbsp;Tetsuhiro Yoshinami,&nbsp;Tomonori Tanei,&nbsp;Kenzo Shimazu","doi":"10.1016/j.ctarc.2026.101216","DOIUrl":"10.1016/j.ctarc.2026.101216","url":null,"abstract":"<div><div>Background. Omission of axillary lymph node dissection (ALND) in patients with positive sentinel lymph nodes (SLN) who underwent mastectomy remains controversial. In this study, we reported the omission of ALND in mastectomy cases with positive SLNs, using a nomogram to predict non-SLN metastasis. Furthermore, we reported the management of patients with more than four metastatic axillary lymph nodes (ALN). Methods. We prospectively identified 392 patients with primary invasive breast cancer (cT1–3, N0) who underwent a mastectomy and were diagnosed with SLN metastasis using one-step nucleic acid amplification (OSNA). We used our predictive nomogram, including the OSNA factor for patients with positive SLNs, to make decisions regarding ALND and determine the probability of four or more axillary lymph node metastases. Results. Of the 392 patients, 124 (31.3%) had one or two metastases to the SLNs, and 31 (25.0%) had a predictive probability of a nomogram for metastasis to non-SLNs (</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101216"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147739756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of pap smear for cervical intraepithelial neoplasia in women with treatment-resistant vaginal infections: A colposcopy-guided biopsy correlated study","authors":"Mohades Peydayesh,&nbsp;Somayeh Nikfar,&nbsp;Kimia Ghasemi,&nbsp;Narges Zamani","doi":"10.1016/j.ctarc.2026.101237","DOIUrl":"10.1016/j.ctarc.2026.101237","url":null,"abstract":"<div><h3>Background</h3><div>The present study was conducted to investigate the value of Pap smear in the diagnosis of cervical intraepithelial neoplasia compared to colposcopy results in patients suffering from medication-resistant vaginal infection.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective diagnostic accuracy study was conducted on 975 female patients with medication-resistant vaginal infection who referred to our tertiary hospital between 2018 and 2023 and met the inclusion criteria. All demographic and clinical information, including Pap smear and colposcopy results, were extracted from the files and collected using a researcher-made questionnaire. All information was statistically analyzed using SPSS and MedCalc software.</div></div><div><h3>Results</h3><div>The mean age of the patients was 34.63 ± 8.38 years. The most common cause of referral for colposcopy was treatment-resistant vaginal discharge (74.6 %). In Pap smear results, 33.2 % of cases were reported as normal. Also, mild, moderate, and severe inflammation were found in 12.1 %, 2.4 %, and 3.5 % of the cases, respectively. The high percentage of ASCUS, LSIL, and HSIL was 39.8 %, 5.3 %, and 1.3 %, respectively. In colposcopy, 38.7 %, 52.6 %, 7.5 %, and 1.2 % of the cases had cervicitis, CIN-1, CIN-2 and CIN-3, respectively. Also, Pap smear in CIN screening had a sensitivity, specificity, positive predictive value, and negative predictive value of 50.6 %, 54.1 %, 63.7 %, and 40.8 %, respectively.</div></div><div><h3>Discussion</h3><div>Considering the low sensitivity and specificity of Pap smear results in diagnosing CIN lesions in women with treatment-resistant vaginal discharge, it is recommended to use complementary methods in addition to Pap smear.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101237"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147958769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second primary malignancies after stereotactic body radiotherapy vs surgery for early-stage lung cancer: a U.S. population-based study, 2010-2015","authors":"Lianfang Ni,&nbsp;Zhigang Zhang,&nbsp;Zhonghui Liu,&nbsp;Xinmin Liu","doi":"10.1016/j.ctarc.2026.101211","DOIUrl":"10.1016/j.ctarc.2026.101211","url":null,"abstract":"<div><h3>Background</h3><div>Stereotactic body radiotherapy (SABR) plays an essential role in the curative treatment of early-stage lung cancer. Second primary malignancy (SPM) has become a significant concern in lung cancer management because of the increasing number of cancer survivors. However, whether SABR increases the risk of SPMs in early-stage lung cancer remains unknown.</div></div><div><h3>Methods</h3><div>Patients with T1–2N0M0 primary lung cancer who underwent either surgery or SABR between 2010 and 2015 were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. A Kaplan–Meier analysis was conducted to compare the cumulative incidence of SPMs between patients who underwent radiotherapy and those who underwent surgery. Multivariable Cox regression analyses were performed to evaluate the risk of SPMs.</div></div><div><h3>Results</h3><div>The study included 22,809 2-year early-stage lung cancer survivors (radiotherapy, 3236; surgery, 19,573) and 17,048 5-year survivors (radiotherapy, 1501; surgery, 15,547). 196 second haematologic cancers and 1642 second solid malignancies were diagnosed. SABR was not associated with a higher overall risk of second haematologic cancers or second solid malignancies. However, after adjusting for independent influencing factors of SPMs, SABR was associated with a 38.5% higher cumulative incidence of secondary primary lung cancer. The risk was increased only when compared to the lobectomy group.</div></div><div><h3>Conclusions</h3><div>SABR for early-stage lung cancer was not associated with a higher overall risk of developing SPMs; however, it did increase the risk of second primary lung cancers when compared to the lobectomy group. Randomised controlled trials should be conducted in the future to validate our conclusions further.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101211"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147702764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?","authors":"Angelo Porreca ,&nbsp;Filippo Marino ,&nbsp;Davide De Marchi ,&nbsp;Marco Giampaoli ,&nbsp;Daniele D'Agostino ,&nbsp;Antonio Amodeo ,&nbsp;Paolo Corsi ,&nbsp;Francesco Claps ,&nbsp;Luca Di Gianfrancesco","doi":"10.1016/j.ctarc.2026.101181","DOIUrl":"10.1016/j.ctarc.2026.101181","url":null,"abstract":"<div><h3>Introduction</h3><div>Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is standard for muscle-invasive bladder cancer (MIBC), yet complete pathological response (ypT0) occurs in only a minority of patients. Its clinical and temporal predictors remain poorly defined, limiting optimized patient selection and treatment timing.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively analyzed 35 consecutive patients with MIBC (≤cN1M0) who achieved ypT0 after NAC followed by robot-assisted radical cystectomy (RARC) and compared them with 70 consecutive patients with residual disease (≥ypT1) treated at the same institution. Descriptive analyses were performed, followed by multivariable multinomial logistic regression to identify independent clinical and treatment-timing predictors of ypT0.</div></div><div><h3>Results</h3><div>Early initiation of NAC within one month of diagnosis (p=0.004), completion of chemotherapy within two months (p=0.003), completion of all planned cycles (p=0.02), favorable clinical restaging prior to RARC (p&lt;0.001), and surgery within an optimal post-chemotherapy recovery window (p=0.01) were significantly associated with ypT0. On multivariable analysis, independent predictors of ypT0 included age &lt;70 years (OR=10.5), early treatment initiation (OR=51.1), timely completion of NAC (OR=25.5), completion of all cycles (OR=44.4), surgery within the optimal recovery interval (OR=19.1), total treatment-to-surgery interval &lt;6 months (OR=35.6), and lower tumor stage at restaging (OR=9.34).</div></div><div><h3>Conclusions</h3><div>This study identified independent clinical and temporal predictors of complete pathological response following NAC and RARC for MIBC. Modifiable timing-related factors—including early treatment initiation, chemotherapy completion, and optimized surgical scheduling—were key to achieving ypT0, supporting improved patient selection and coordinated perioperative care in future studies.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101181"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}